Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ: HRMY )

34.06 -0.89 (-2.55%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
Via ACCESSWIRE
NASDAQ:HRMY is not too expensive for the growth it is showing.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. 
Via Chartmill
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
Via ACCESSWIRE
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. 
Via Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
Earnings Outlook For Harmony Biosciences
Via Benzinga
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
Via Benzinga
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
The company is focused on developing its pipeline of sleep and epilepsy drugs. 
Via Investor's Business Daily
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026. 
Via Benzinga
Unveiling 6 Analyst Insights On Harmony Biosciences
Via Benzinga
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
Key Takeaways From Harmony Biosciences Analyst Ratings
Via Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Via Benzinga
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
From Harmony Biosciences
Via GlobeNewswire
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Analyst Ratings For Harmony Biosciences
Via Benzinga
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with... 
Via Benzinga
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
Updates: HRMY, MELI, SWAV
​​​​​​​Another day, another slew of quarterly update reports for our followed stocks. 
Via Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.